Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 6:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 281 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo 50 or 100 mg Clear all
Active, not recruiting Phase 3 Interventional

Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients

NCT04824092
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma
Interventions
Tafasitamab, Lenalidomide, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Tafasitamab placebo, Lenalidomide placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
899 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
47
States / cities
Daphne, Alabama • Anaheim, California • Clovis, California + 44 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 11, 2026, 6:14 AM EDT
Completed Phase 2 Interventional Results available

NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)

NCT01688037
View directory record Official record
Conditions
Tardive Dyskinesia
Interventions
NBI-98854, Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 85 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
49
States / cities
Little Rock, Arkansas • Anaheim, California • Carson, California + 41 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Oct 11, 2026, 6:14 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis

NCT02437162
View directory record Official record
Conditions
Axial Spondyloarthritis
Interventions
Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg, Golimumab 50 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
11
States / cities
Peoria, Arizona • St. Petersburg, Florida • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 11, 2026, 6:14 AM EDT
Completed Phase 2 Interventional Results available

Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP)

NCT01594827
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Inhaled Vancomycin, Placebo (Sterile Water), Rifampin, Trimethoprim/Sulfamethoxazole (TMP/SMX), Doxycycline, Mupirocin Intranasal Creme, 4% chlorhexidine gluconate liquid skin cleanser
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 11, 2026, 6:14 AM EDT
Recruiting No phase listed Observational

Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

NCT00576069
View directory record Official record
Conditions
Asthma
Interventions
budesonide/formoterol, fluticasone/salmeterol, mometasone/formoterol, Prednisone
Drug
Lead sponsor
Gelb, Arthur F., M.D.
Individual
Eligibility
10 Years to 95 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
1
States / cities
Lakewood, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 11, 2026, 6:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First Time in Human Study of Protexia

NCT00744146
View directory record Official record
Conditions
Intervention for Nerve Agent Exposure
Interventions
Protexia
Biological
Lead sponsor
PharmAthene, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2010 · Synced Oct 11, 2026, 6:14 AM EDT
Completed Phase 3 Interventional

A New Sildenafil Oral Film in Patients With Erectile Dysfunction

NCT05490680
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
Sildenafil Oral Film 25 mg, 50 mg, 75 mg or 100 mg, Placebo
Drug
Lead sponsor
IBSA Institut Biochimique SA
Industry
Eligibility
18 Years and older · Male only
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
18
States / cities
Foley, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 11, 2026, 6:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA)

NCT00983255
View directory record Official record
Conditions
Bacterial Infections
Interventions
TR-701 FA for injection, 200 mg/vial, TR-701 FA tablets
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 50 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Oct 11, 2026, 6:14 AM EDT
Completed Phase 2 Interventional

Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Coronary Artery Disease

NCT00312052
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
E5555, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
45 Years to 80 Years
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Gainesville, Florida • Alpena, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 5, 2016 · Synced Oct 11, 2026, 6:14 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Repeat Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects

NCT02289495
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK2838232, Placebo, Ritonavir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 11, 2026, 6:14 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus

NCT02000700
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Canagliflozin 100 mg, Canagliflozin 50 mg, Canagliflozin 300 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
10 Years to 17 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
13
States / cities
Little Rock, Arkansas • Los Angeles, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 11, 2026, 6:14 AM EDT
Recruiting Phase 3 Interventional

A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata

NCT07733765
View directory record Official record
Conditions
Alopecia Areata
Interventions
Ritlecitinib 100 mg, Ritlecitinib 50 mg, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
17
States / cities
Encinitas, California • Miami, Florida • Skokie, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 11, 2026, 6:14 AM EDT
Terminated Phase 2 Interventional Results available

A Study of LY2599506 in Patients With Type 2 Diabetes

NCT01024244
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, LY2599506
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Topeka, Kansas • Toms River, New Jersey • Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Dec 2, 2011 · Synced Oct 11, 2026, 6:14 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Armodafinil as Adjunctive Therapy in Schizophrenic Adults With Cognitive Deficits

NCT00487942
View directory record Official record
Conditions
Schizophrenia
Interventions
armodafinil, placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
12
States / cities
Garden Grove, California • National City, California • Paramount, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2013 · Synced Oct 11, 2026, 6:14 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications

NCT02408523
View directory record Official record
Conditions
Epilepsy
Interventions
Lacosamide Tablet, Lasosamide Oral Solution, Placebo Tablet, Placebo Oral Solution
Drug · Other
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
4 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
27
States / cities
Alabaster, Alabama • Little Rock, Arkansas • Irvine, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 11, 2026, 6:14 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study of PER977 Administered to Subjects With Steady State Edoxaban Dosing and Re-anticoagulation With Edoxaban

NCT02207257
View directory record Official record
Conditions
Anticoagulation Reversal
Interventions
PER977, Placebo, Edoxaban
Drug
Lead sponsor
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 21, 2020 · Synced Oct 11, 2026, 6:14 AM EDT
Completed Phase 2 Interventional Results available

A Clinical Trial to Test a Study Drug in Volunteers Who Develop Asthma Following Exercise

NCT00812929
View directory record Official record
Conditions
Asthma
Interventions
Placebo, GSK2190915
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Denver, Colorado • North Dartmouth, Massachusetts • Oklahoma City, Oklahoma + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2017 · Synced Oct 11, 2026, 6:14 AM EDT
Completed Phase 2 Interventional Results available

Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

NCT00481195
View directory record Official record
Conditions
Bipolar I Depression
Interventions
Armodafinil, Placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
42
States / cities
Birmingham, Alabama • Escondido, California • Lafayette, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2013 · Synced Oct 11, 2026, 6:14 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)

NCT05630755
View directory record Official record
Conditions
HIV-1 Infection
Interventions
DOR/ISL, BIC/FTC/TAF, Placebo to BIC/FTC/TAF, Placebo to DOR/ISL
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
24
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 11, 2026, 6:14 AM EDT
Completed Phase 2 Interventional Results available

A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery

NCT03891524
View directory record Official record
Conditions
Arthroplasty, Replacement, Knee
Interventions
JNJ-70033093 25 mg, JNJ-70033093 50 mg, JNJ-70033093 100 mg, JNJ-70033093 200 mg, Placebo, Enoxaparin 40 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
50 Years and older
Enrollment
1,242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
9
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 11, 2026, 6:14 AM EDT
Terminated Phase 2 Interventional Results available

Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)

NCT03345407
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Placebo ELLIPTA, Nemiralisib ELLIPTA 50 µg, Nemiralisib ELLIPTA 100 µg, Nemiralisib ELLIPTA 250 µg, Nemiralisib ELLIPTA 500 µg, Nemiralisib ELLIPTA 750 µg, Albuterol (Salbutamol) MDI or nebules, Standard of care therapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
943 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
21
States / cities
Mobile, Alabama • Colorado Springs, Colorado • Daytona Beach, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Oct 11, 2026, 6:14 AM EDT
Completed Phase 1Phase 2 Interventional

To Study the Use of Humanized CD25 in Preventing the Relapse of Psoriasis Vulgaris

NCT00050661
View directory record Official record
Conditions
Psoriasis
Interventions
Daclizumab, NB-UVB
Drug · Device
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2008
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 25, 2009 · Synced Oct 11, 2026, 6:14 AM EDT
Completed Phase 3 Interventional Results available

Vitamin C, Thiamine, and Steroids in Sepsis

NCT03509350
View directory record Official record
Conditions
Sepsis
Interventions
Vitamin C, Thiamine, Hydrocortisone, Vitamin C Placebo, Thiamine Placebo, Hydrocortisone Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
43
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 11, 2026, 6:14 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study Evaluating the Effect of Albiglutide on Gallbladder Emptying in Healthy Subjects

NCT02496221
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Albiglutide 50 mg, Placebo, CCK (Kinevac)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 11, 2026, 6:14 AM EDT